Mercer Global Advisors
CRDL

Mercer Global Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Mercer Global Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Hold
22,600
– – ﹤0.01% 3584
2026
Q1 		$30.5K Hold
22,600
– – ﹤0.01% 3167
2025
Q4 		$21.6K Hold
22,600
– – ﹤0.01% 2819
2025
Q3 		$24.2K Hold
22,600
– – ﹤0.01% 2613
2025
Q2 		$30.7K Buy
+22,600
New +$26.3K ﹤0.01% 2214

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mercer Global Advisors's CRDL Position: Q2 2026 in Review

Mercer Global Advisors held its Cardiol Therapeutics (CRDL) position steady in Q2 2026 at 22,600 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #3584.

Mercer Global Advisors first reported a position in CRDL in Q2 2025 and has held it in 5 quarters since. The position peaked at $30.7K in Q2 2025. 51 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Mercer Global Advisors held 22,600 shares of Cardiol Therapeutics worth $24K as of Q2 2026.
  • Mercer Global Advisors left its Cardiol Therapeutics share count unchanged in Q2 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3584 holding.
  • Mercer Global Advisors first reported a position in Cardiol Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Mercer Global Advisors's Cardiol Therapeutics position peaked at $30.7K in Q2 2025.
  • 51 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.